This study implicates the therapeutic potential of SNRPD1 in breast cancer control that might be expanded to other types of cancers and warrants the combined use of doxorubicin and drugs targeting SNRPD1 in treating triple negative breast cancers, which are subjected to experimental validations. The gene discussed is SNRPD1; the disease is breast carcinoma.